MetaCap

Kazia Therapeutics (KZIA) vs Rani Therapeutics (RANI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kazia Therapeutics (KZIA) has outperformed Rani Therapeutics (RANI) over the past year, losing 41.1% versus a loss of 68.6%. Over five years, RANI leads with a -98.3% price change compared with -99.0% for KZIA. Rani Therapeutics is the larger company by market cap ($59.0 million vs $56.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KZIA-41.08%RANI-68.64%
+111%+17%-77%
Nov 21, 20251 yearNov 20, 2026
KZIA-99.13%RANI-98.50%
+5%-50%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KZIA versus RANI key metrics
MetricKZIARANI
Share price$4.92$0.5111
Market cap$56.22M$59.03M
1-day change-8.38%-11.97%
YTD return-28.59%-62.14%
1-year return-41.08%-68.64%
5-year return-99.01%-98.34%
EPS (TTM)$-6.85$-0.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.63M
Revenue growth (YoY)—+58.85%
Net income (latest FY)—$-29.67M
Operating margin—-2345.99%
Net margin—-1817.09%
52-week high$17.40$1.69
52-week low$4.50$0.502
Distance from 52-week high-71.72%-69.76%
Analyst consensusnonestrong_buy
Avg. price target upside+476.02%+1308.73%
Average volume307.30K545.67K
Shares outstanding11.43M115.49M
Employees669
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KZIA has outperformed RANI by 27.6 percentage points over the past year.

About Kazia Therapeutics

KZIA stock →

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Rani Therapeutics

RANI stock →

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

KZIA vs RANI FAQ

Which is bigger, Kazia Therapeutics or Rani Therapeutics?

Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $56.22M for Kazia Therapeutics (KZIA).

Which stock has performed better over the past year, KZIA or RANI?

KZIA returned -41.08% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.

Are Kazia Therapeutics and Rani Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons